
    
      The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence
      Study with a washout period of 14 days. During each session, the subjects will be
      administered a single dose of 5mg amlodipine (one LANDI-Amlodipine Tablet 5mg or one Norvasc
      Tablet 5mg) under fasting and FED conditions.
    
  